Aratana Therapeutics (PETX) Bolts on FDA Nod for Galliprant

Aratana Therapeutics Inc (NASDAQ: PETX) shares rose 6.6% to $3.40 following news that the company has filed for the first FDA approval of Galliprant. Share volume totaled 54,000 compared to an all-day average of 157,000